Proposed is a microneedle patch including a body in which at least one opening is formed, and a microneedle body which is disposed in the opening and has at least one microneedle formed therein, wherein when an external force is applied in a first direction, the microneedle body moves in the first direction so as to administer a drug in the microneedle to a user’s skin.

Disclosed herein are compositions and methods related to megakaryocyte-derived extracellular vesicles derived from human pluripotent stem cells, where the megakaryocyte-derived extracellular vesicles may be utilized for drug delivery and treating various diseases.

Devices and methods are provided for administering a drug to a biological tissue in a patient, such as by intracellular and/or dermal delivery. The device includes a piezoelectric pulse generator; and an array of microneedle electrodes electrically coupled to the piezoelectric pulse generator, wherein the device, following insertion of the microneedle electrodes into the biological tissue, is configured to generate and deliver one or more electrical pulses through the microneedle electrodes effective to electroporate cells in the biological tissue and enable delivery of a drug into the electroporated cells.

The present invention relates to a microcontainer microstructure including a microcontainer film structure having a sharp tip portion and a method of manufacturing the same.

Proposed is a patch for the alleviation and prevention of acne, in which anti-acne activity of a biodegradable metal represented by Mg.sub.aZn.sub.bX.sub.c (in which a, b and c are wt % of individual components, a+b+c=100 wt %, 0≤a≤100, 0≤b≤100, and 0≤c≤10, among which a or b is the greatest, and X is at least one selected from the group consisting of Ca, Fe, Mn, Si, Na, Zr, Ce, and P) is demonstrated, thus exhibiting novel use thereof as a patch for the alleviation and prevention of acne.

The present invention provides a microneedle device comprising: a substrate; a microneedle disposed on the substrate; and a coating layer formed on the microneedle; in which the coating layer comprises a recombinant follicle-stimulating hormone, arginine, and glycerin, in the coating layer, the mass of arginine is 0.07 to 0.75-fold of the mass of the recombinant follicle-stimulating hormone and the mass of glycerin is 0.1 to 2.75-fold of the mass of the recombinant follicle-stimulating hormone.

The present invention provides a biodegradable microdepot delivery system for topical delivery of active ingredients through the skin surface of a subject. The configuration, dimension, and chemical composition of the microdepots allow a relatively short dissolution time of less than 5 minutes while insertion ratio of the microdepots can reach more than 60%, some of which can even reach about 97%, under exertion of a relatively low pressing force. The present invention also provides a method for fabricating the biodegradable microdepot delivery system and a polymeric solution for forming the same.

A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection.

The object of the present invention is a device (1) for the transdermal delivery of active molecules. The device (1) comprises a support element (8) and a plurality of micro-needles (10) that protrude from a first surface of the support element (8), the support element (8) and the micro-needles (10) being both permeable to the active molecules. The device (1) further comprises a porous membrane (7) configured to be loaded with said active molecules, which lies on a second surface of the support element (8). Characteristically, the porous membrane (7) is configured to behave, from an optical viewpoint, as a Bragg mirror. Further objects of the present invention are the following uses of the device (1): for monitoring the release and/or the decay of the active molecules, for the optical control of the release of the active molecules and for the thermal control of the release of the active molecules. Lastly, an object of the present invention is the method for producing the device (1) for transdermal delivery of active molecules.

An intradermal delivery system comprises an immunogenic composition comprising a TLR agonist and immunogen and a microneedle. The immunogenic composition may comprise a solid biodegradable microneedle or a solid coated microneedle. The intradermal delivery system may be formulated into a skin patch.